Swedish Orphan Biovitrum (1SOBI) Stock Overview

A biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. More details

1SOBI fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	4/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 58.7% below our estimate of its fair value

Earnings are forecast to grow 25.83% per year

Trading at good value compared to peers and industry

Risk Analysis

Large one-off items impacting financial results

Significant insider selling over the past 3 months

Profit margins (3.2%) are lower than last year (15.1%)

Has a high level of debt

+ 1 more risk

1SOBI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW488,522 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

488,522 investors already sharing narratives

View all narratives

Swedish Orphan Biovitrum AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Swedish Orphan Biovitrum
Historical stock prices
Current Share Price	SEK 41.70
52 Week High	SEK 42.24
52 Week Low	SEK 26.52
Beta	0.29
1 Month Change	4.09%
3 Month Change	5.14%
1 Year Change	71.60%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	51.09%

Recent updates

Shareholder Returns

	1SOBI	IT Biotechs	IT Market
7D	-2.8%	-1.3%	-0.5%
1Y	71.6%	35.8%	24.2%

Return vs Industry: 1SOBI exceeded the Italian Biotechs industry which returned 35.8% over the past year.

Return vs Market: 1SOBI exceeded the Italian Market which returned 24.2% over the past year.

Price Volatility

Is 1SOBI's price volatile compared to industry and market?
1SOBI volatility
1SOBI Average Weekly Movement	6.5%
Biotechs Industry Average Movement	7.6%
Market Average Movement	4.6%
10% most volatile stocks in IT Market	8.1%
10% least volatile stocks in IT Market	3.0%

Stable Share Price: 1SOBI's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: 1SOBI's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Italian stocks.

About the Company

Founded	Employees	CEO	Website
1939	1,969	Guido Oelkers	www.sobi.com

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma.

Swedish Orphan Biovitrum AB (publ) Fundamentals Summary

How do Swedish Orphan Biovitrum's earnings and revenue compare to its market cap?
1SOBI fundamental statistics
Market cap	€14.47b
Earnings (TTM)	€83.45m
Revenue (TTM)	€2.62b

173.4x

P/E Ratio

5.5x

P/S Ratio

Is 1SOBI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1SOBI income statement (TTM)
Revenue	SEK 28.96b
Cost of Revenue	SEK 6.17b
Gross Profit	SEK 22.78b
Other Expenses	SEK 21.86b
Earnings	SEK 921.00m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Oct 27, 2026

Earnings per share (EPS)	2.66
Gross Margin	78.68%
Net Profit Margin	3.18%
Debt/Equity Ratio	46.3%

How did 1SOBI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/18 01:47
End of Day Share Price	2026/07/17 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Swedish Orphan Biovitrum AB (publ) is covered by 29 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Brian Balchin	Barclays
James Gordon	Barclays

Swedish Orphan Biovitrum (1SOBI) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Swedish Orphan Biovitrum AB (publ) Competitors

Philogen

Recordati Industria Chimica e Farmaceutica

Exelixis

Sichuan Kelun-Biotech Biopharmaceutical

Price History & Performance

Recent News & Updates

New minor risk - Financial position

Second quarter 2026 earnings released: EPS: kr3.17 (vs kr1.85 in 2Q 2025)

Swedish Orphan Biovitrum AB (publ) Announces Positive Reimbursement Recommendation For EMPAVELI (Pegcetacoplan) For Treatment Of C3G And Primary IC-MPGN In Canada

Sobi Receives Complete Response Letter From Food And Drug Administration for NASP

Swedish Orphan Biovitrum Receives Complete Response Letter from Fda for Nasp

Sobi Presents New Clinical and Real-World Data for Aspaveli, Doptelet, Gamifant, and Vonjo At Eha 2026

Recent updates

New minor risk - Financial position

Second quarter 2026 earnings released: EPS: kr3.17 (vs kr1.85 in 2Q 2025)

Swedish Orphan Biovitrum AB (publ) Announces Positive Reimbursement Recommendation For EMPAVELI (Pegcetacoplan) For Treatment Of C3G And Primary IC-MPGN In Canada

Sobi Receives Complete Response Letter From Food And Drug Administration for NASP

Swedish Orphan Biovitrum Receives Complete Response Letter from Fda for Nasp

Sobi Presents New Clinical and Real-World Data for Aspaveli, Doptelet, Gamifant, and Vonjo At Eha 2026

Swedish Orphan Biovitrum AB Announces Results From New Analysis Of Tryngolza Phase 3 CORE And CORE2 Trials

Swedish Orphan Biovitrum AB Announces Positive Topline Results from Pivotal Phase 3 Reduce 2 Study of Pozdeutinurad in Gout

Swedish Orphan Biovitrum AB (publ) Elects Board Members

Swedish Orphan Biovitrum AB (publ) Reaffirms Earnings Guidance for the Year 2026

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2026 Results on Feb 04, 2027

New minor risk - Financial position

First quarter 2026 earnings released: EPS: kr3.81 (vs kr2.55 in 1Q 2025)

Swedish Orphan Biovitrum AB (publ) Receives Health Canada Approval for EMPAVELI (Pegcetacoplan) for Treatment of C3G and Primary IC-MPGN

Full year 2025 earnings released: EPS: kr1.39 (vs kr11.37 in FY 2024)

Sobi Validates Indication Extension Application for Tryngolza (Olezarsen) for the Treatment of Severe Hypertriglyceridemia

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 06, 2026

Swedish Orphan Biovitrum AB Presents Topline Results from Embrace Phase 2A Study of Emapalumab in Interferon-Gamma-Driven Sepsis

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of Arthrosi Therapeutics, Inc.

Full year 2025 earnings released: EPS: kr1.39 (vs kr11.37 in FY 2024)

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for the Fiscal Year 2026

Less than half of directors are independent

Sobi Announces to Advance Gamifant (Emapalumab) in Interferon-Gamma-Driven Sepsis (IDS) Based on EMBRACE Topline Data

New minor risk - Share price stability

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement to acquire Arthrosi Therapeutics, Inc. for $1.5 billion.

Sobi Receives Positive CHMP Opinion for Aspaveli®? (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

Less than half of directors are independent

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2025 Final Results on Mar 31, 2026

CEO & President recently sold €2.4m worth of stock

Less than half of directors are independent

Sobi North America Announces the Presentation of Data Across Its Immunology Portfolio

Sobi Showcases New Data Across Rare Infusion Conditions At ACR 2025

Sobi Announces Resignation of Helena Saxon as Member of Board of Director, Effective October 21, 2025

Swedish Orphan Biovitrum AB (Publ) Revises Earnings Guidance for the Fiscal Year 2025

Sobi and Ionis Pharmaceuticals, Inc. Announces Approval in the European Union for Familial Chylomicronemia Syndrome

Less than half of directors are independent

Sobi North America Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment ofThrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia

Swedish Orphan Biovitrum AB (publ) Provides Unchanged Earnings Guidance for the Year 2025

Sobi Announces U.S. Food and Drug Administration Approves Gamifant® (emapalumab-lzsg) as First-Ever Treatment for Adults and Children with Macrophage Activation Syndrome in Still's Disease

Apellis Pharmaceuticals, Inc. and Sobi Announce EMPAVELI®? (Pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

Sobi Showcases Breadth of Data in C3G/ Primary IC-MPGN at ERA 2025

Swedish Orphan Biovitrum AB (Publ) Appoints Iris Loew-Friedrich as Board Member

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2025 Results on Feb 05, 2026

Less than half of directors are independent

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 08, 2025

Sobi Announces Research Collaboration Involving New Phase 2a Clinical Trial for Gamifant

Swedish Orphan Biovitrum AB (publ) to Report Q1, 2025 Results on Apr 29, 2025

Shareholder Returns

Price Volatility

About the Company

Swedish Orphan Biovitrum AB (publ) Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources